Original article

Survival results with the Use of Chemoradiotherapy in the Treatment of Locally Advanced Non-Small Cell Lung Cancer

Hanan Gamal-Elddeen Mostafa

Department of Clinical Oncology, Faculty of Medicine Assiut University, Assiut, Egypt

Background: A combination of chemotherapy (CT) and radiotherapy (RT) is the treatment base for locally advanced non-small cell lung cancer (NSCLC). The aim of this work was to compare the survival impact of concomitant versus sequential CT and RT for inoperable (stage III) NSCLC.

Patients and Methods: The patients presented with stage III NSCLC, divided into 2 groups, group A treated with cisplatin 60mg/m², day1 plus etoposide 100mg/m²/ day, days1-3 and after 3 weeks RT (60 Gy in 30 fractions) started with weekly cisplatin 20mg/ m² for 6 weeks followed by 3 cycles of the same CT after the end of RT. Group B treated with the same CT for 3 cycles followed by the same RT protocol, and then 3 cycles after the end of radiotherapy.

Results: The overall response rates were 55% in the concurrent group and 40% in the sequential group. Median survival was significantly longer in the concurrent group 20 months versus 12 months in the sequential group (P< 0.001). Progression free survival was significantly longer in the concurrent group 15 months versus 9 months in the sequential group (P< 0.001). Toxicity was more frequent in the concurrent than in the sequential group with a significant greater incidence of leucopenia, esophagitis, nausea and vomiting (P< 0.001).

Conclusion: In this study population, concurrent CRT demonstrated significant benefit in terms of overall and progression-free survival over sequential CRT but at the cost of increased toxicity.

Key words: Non-small cell lung cancer, stage III, chemoradiotherapy, cisplatin and etoposide.

Corresponding Author: Hanan Gamal El-deen Mostafa  E-mail: mostafahanan36@yahoo.com
A meta-analysis was published to clarify whether concurrent or sequential treatment is better. This included 1,205 patients with 6-years follow-up and demonstrated that concomitant treatment contributed absolute benefit overall survival at 5 years of 4.5% over sequential treatment, but at the cost of increasing toxicity in the form of grade 3-4 esophagitis.

The aim was to compare between sequential and concomitant chemotherapy and radiotherapy in patients with advanced inoperable non-small cell lung cancer.

PATIENTS AND METHODS

This randomized single-blind phase III study was conducted in Clinical Oncology department, Assiut University Hospital. The study included 40 patients in each group, treated between January 2005 and September 2008. The study included patients with inoperable locally advanced (stage III) non-small cell lung cancer (staging of American Joint Committee on Cancer 6th ed. 2002).

Eligibility criteria:
Inclusion criteria were, age 41-85 years, histopathologically proven, locally advanced unresectable non metastatic NSCLC, bidimensionaly measurable disease, no previous treatment by radiotherapy or chemotherapy, Eastern Cooperative Oncology Group performance status <2, adequate hematologic, hepatic and renal functions.

Exclusion criteria included pleural or pericardial effusion, extensive vessel invasion, a diagnosis of small-cell lung cancer, previous treatment with chemotherapy or radiotherapy to lung cancer and impaired renal functions.

All eligible patients gave their informed consent prior to the inclusion in the study.

Treatment plan:
The sample size was calculated by using the formula of randomized controlled trials. Eighty eligible patients were divided into two groups each group included forty patients. Both groups were balanced in their clinicopathological features.

Group A included forty patients were treated with one cycle of cisplatin 60 mg/m² (one hour i.v. infusion) on day 1 plus etoposide 100mg/m²/day (30 minutes i.v. infusion) on days 1-3. Radiotherapy was given concomitant with weekly cisplatin 20mg/ m² 30 minutes infusion on day one of the second cycle chemotherapy for 6 weeks. Radiotherapy was administered 2 hours after completion of chemoradiotherapy infusion. Three cycles of the same chemotherapy every 21 days were administered after completing radiotherapy. All patients received intravenous antiemetic on day 1 with pre- and postchemotherapy hydration.

Radiotherapy consisted of a total dose 60Gy in 30 fractions over 6 weeks (2Gy/fraction for 5 days, each week) using linear accelerator 6MV, two-dimensional radiotherapy. The radiation dose was administered to a planning target volume that included computed tomography visible primary tumor (pre-chemotherapy tumor volume) plus 1cm margins in the transverse diameter and 1.5-2 cm margins in the vertical direction to account for daily setup errors and target motion, it also included elective irradiation of ipsilateral, contralateral hilar, mediastinal, subcarinal and occasionally supraclavicular areas in cases with upper lobe tumors involvement. This is phase I and 40 Gy was delivered by parallel opposing anteroposterior and posteranterior fields. Second phase radiotherapy was delivered to the primary tumor, ipsilateral hilar lymph nodes and 1 cm margin for organ motion during treatment with a direct lateral field had a gantry angle of 90°, weighted down to 50% to reduce irradiation to the opposite lung. Other fields included anterior 30° wedge field with a gantry angle 0° and a posterior oblique wedge field had a gantry angle of 140°. Phase II delivered 20 Gy.

Group B included forty patients were treated with three cycle of cisplatin 60mg/m² on day 1 and etoposide 100mg/m² on days1-3 every 3 weeks followed by the same radiotherapy protocol. Three cycles of cisplatin and etoposide were given after the end of radiotherapy.

Patient evaluation:
All patients underwent a full physical examination, assessment for hematology, renal functions and toxicity. This assessment was conducted every 3 weeks before chemotherapy and again before and after radiation therapy.

Chest x-ray, computed tomography (CT) scan including upper abdomen to assess liver and adrenal gland status were performed before treatment and was repeated 4 weeks after the end of treatment.

Bone scan was performed to all patients before treatment, but brain CT scan was performed if clinically indicated.

Tissue diagnosis was made using biopsy/ brush or bronchial aspirate obtained during fibreoptic bronchoscope.
After completion of study treatment, patients were follow-up every month until disease progression, for a maximum of one year from the date of the last chemotherapy treatment.

Any treatment related side effects recorded and were followed up until resolution.

Tumor response was assessed according to World Health Organization (WHO) criteria\(^\text{10}\). Progression free survival (PFS) was defined as the time from the start of chemotheraphy until the date of progression. Overall survival (OS) was determined from the start of chemotheraphy to the date of death or last follow-up.

Toxicity was assessed using National Cancer Institute-Common Toxicity Criteria (NCI-CTC) version 2.0.

**Statistical methods:**

The primary end points of this study were overall survival (OS) and Progression-free survival (PFS). Secondary end points were response rate and toxicity evaluation of sequential and concomitant chemoradiotherapy. Chi-square test was used to compare differences in distribution of frequencies among various groups of response. P-value 0.05 was considered significant. Overall survival and progression-free survival were calculated using Kaplan-Meier method\(^\text{11}\).

**RESULTS**

Eighty patients were included between January 2005 and September 2008. Patients were divided into two groups, group A included forty patients who were treated by concomitant chemoradiotherapy and group B included forty patients who were treated by sequential chemoradiotherapy.

Table (1) shows the baseline patient and tumor characteristics. Both groups were well balanced in their clinico-pathological characteristics except for the percentage of males is significantly higher in group B. Most patients had stage IIIB and squamous cell carcinoma was the commonest histology (55% & 45% in group A&B, respectively).

Table (2) shows the response rate at study end. There was no significant difference in response between the two groups but partial response was 55% (22/40) in group A which was higher than the partial response rate in group B 40% (16/40). The percentage of patients with progressive disease was 7.5% (3/40) and 25% (10/40) in the group A and B respectively which indicate a better response to concomitant chemoradiotherapy.

Table (3) shows the difference in response rate in patients with stage IIIA and stage IIIB disease who received concomitant chemoradiotherapy and sequential chemoradiotherapy. The partial response rate is significantly higher in patients with stage III A who were treated with concurrent versus sequential chemoradiotherapy (59% vs 41%) and also in patients with stage IIIB (56% vs 44%) \(P<0.01\). The percentage of patients with progressive disease was significantly higher in patients treated with sequential than concomitant chemoradiotherapy, in stage IIIA 80% vs 20% and in stage IIIB 75% vs 25% \(P<0.01\).

Tables 4, 5 show the prognostic factors for response in the two groups. The presence of N2-N3 disease was found as a significant adverse prognostic factor.

Safety and toxicity are reported in Table (6), there was no grade 4 toxicity in both groups but grade 3 toxicity was significantly higher in patients treated with concomitant chemoradiotherapy than sequential. Leucopenia is the most common grade 3 hematological adverse events in both groups, occurring in 20% of patients treated with concomitant chemoradiotherapy which was significantly higher than 5% of patients treated with sequential chemoradiotherapy \((P<0.001)\). Esophagitis, nausea and vomiting were the most frequent treatment related non-hematological toxicity; both were significantly higher in the concomitant chemoradiotherapy group.

Figure (1) shows OS in both groups. The median OS was 12 months (95% CI: 10.67-13.37 months) for patients treated with sequential chemoradiotherapy (group B) and 20 months (95% CI: 18.45-21.54 months) for patients treated with concomitant chemoradiotherapy (group A). The difference in OS was statistically significant \((P<0.001)\).

The 1- and 2-year survival rates were higher in the concurrent arm (68% and 42%, respectively) than in the sequential arm (48% and 24%, respectively).

The 1- and 2-year progression-free survival was also higher in the concurrent arm (60% and 22%, respectively) than in the sequential arm (32% and 8%, respectively).

Figure (2) shows PFS in both groups. Progression-free survival was 9 (95%CI: 8.32-9.67 months) and 15 months (95% CI: 12.52-17.47 months) in patients treated with sequential and concomitant chemoradiotherapy respectively. The difference was statistically significant \((P<0.001)\).
Survival results with the Use of Chemoradiotherapy

Table 1: Clinico-pathological features of both groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>Group A 40 Patients</th>
<th>Group B 40 Patients</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60.17 ± 10.85</td>
<td>59.67 ± 11.50</td>
<td>0.372</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>41 - 84</td>
<td>42.0 - 84.0</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>59.0</td>
<td>62.0</td>
</tr>
<tr>
<td>ECOG Performance status: No (%)</td>
<td>0</td>
<td>24 (60%)</td>
<td>26 (65%)</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>16 (40%)</td>
<td>14 (35%)</td>
</tr>
<tr>
<td>Sex: No (%)</td>
<td>Male</td>
<td>30 (75%)</td>
<td>22 (55%)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>10 (25%)</td>
<td>18 (45%)</td>
</tr>
<tr>
<td>Histopathology: No (%)</td>
<td>Adenocarcinoma</td>
<td>11 (27.5%)</td>
<td>11 (27.5%)</td>
</tr>
<tr>
<td></td>
<td>Large cell carcinoma</td>
<td>2 (5%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td></td>
<td>Squamous cell carcinoma</td>
<td>22 (55%)</td>
<td>18 (45%)</td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td>5 (12.5%)</td>
<td>10 (25.0%)</td>
</tr>
<tr>
<td>Disease stage: No (%)</td>
<td>III A</td>
<td>19 (47.5%)</td>
<td>18 (45.0%)</td>
</tr>
<tr>
<td></td>
<td>III B</td>
<td>21 (52.5%)</td>
<td>22 (55.0%)</td>
</tr>
<tr>
<td>Nodal Status:</td>
<td>N0 – N1</td>
<td>15 (37.5%)</td>
<td>13 (32.5%)</td>
</tr>
<tr>
<td></td>
<td>N2 – N3</td>
<td>25 (62.5%)</td>
<td>27 (67.5%)</td>
</tr>
</tbody>
</table>

ECOG: Eastern Cooperative Oncology Group
* = statistically significant
Group A: concomitant chemoradiotherapy
Group B: sequential chemoradiotherapy

Figure 1: Overall survival (OS) of 40 patients with locally advanced non-small cell lung cancer (NSCLC) treated by concomitant chemoradiotherapy (C-CRT) group A (20 months, 95% CI: 18.4521.54-) versus OS of 40 patients with locally advanced NSCLC treated by sequential chemoradiotherapy (S-CRT) groupB (12 months, 95% CI: 10.6713.32-) P< 0.001. + = censored patient

Figure 2: Progression-free survival (PFS) of 40 patients with locally advanced non-small cell lung cancer (NSCLC) treated by concomitant chemoradiotherapy (C-CRT) group A (15 months, CI: 12.5217.47-) versus PFS of 40 patients with locally advanced NSCLC treated by sequential chemoradiotherapy (S-CRT) group B (9 months, CI: 8.329.67-) P< 0.001. + = censored patients
Table 2: Response rates.

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concomitant chemoradiotherapy (n=40)</td>
<td>22(55%)</td>
<td>15(37.5)</td>
<td>3 (7.5)</td>
<td>0.274</td>
</tr>
<tr>
<td>Sequential chemo-radiotherapy (n=40)</td>
<td>16(40)</td>
<td>14(35)</td>
<td>10(25)</td>
<td></td>
</tr>
</tbody>
</table>

PR: Partial response, SD: Stable disease, PD: Progressive disease

Table 3: Response rate in stage IIIA and IIIB according to the treatment.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-CRT Stage III A (n =19)</td>
<td>13(59)</td>
<td>5(50)</td>
<td>1(20)</td>
<td>0.01*</td>
</tr>
<tr>
<td>S-CRT Stage III A(n=18)</td>
<td>9(41)</td>
<td>5(50)</td>
<td>4(80)</td>
<td></td>
</tr>
<tr>
<td>C-RT Stage IIIB (n=21)</td>
<td>9(56)</td>
<td>10(53)</td>
<td>2(25)</td>
<td>0.01*</td>
</tr>
<tr>
<td>S-CRT Stage IIIB (n=22)</td>
<td>7(44)</td>
<td>9(47)</td>
<td>6(75)</td>
<td></td>
</tr>
</tbody>
</table>

PR: Partial response, SD: Stable disease, PD: Progressive disease
C-CRT: Concomitant chemoradiotherapy, S-CRT: Sequential chemoradiotherapy
* = statistically significant

Table 4: Prognostic factors in Group A (concomitant chemoradiotherapy).

<table>
<thead>
<tr>
<th>Item</th>
<th>PR “n=22”</th>
<th>SD “n=15”</th>
<th>PD “n=3”</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECOG Performance status:</td>
<td>7 (31.8%)</td>
<td>8 (53.3%)</td>
<td>1 (33.3%)</td>
<td>0.411</td>
</tr>
<tr>
<td>• 1</td>
<td>15 (37.5%)</td>
<td>7 (46.7%)</td>
<td>2 (66.7%)</td>
<td></td>
</tr>
<tr>
<td>• 0</td>
<td>12 (54.5%)</td>
<td>9 (60.0%)</td>
<td>1 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>Histology:</td>
<td>6 (27.3%)</td>
<td>4 (26.7%)</td>
<td>1 (33.3%)</td>
<td>0.912</td>
</tr>
<tr>
<td>• Adenocarcinoma</td>
<td></td>
<td>1 (6.7%)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>• Large cell carcinoma</td>
<td>3 (13.6%)</td>
<td>1 (6.7%)</td>
<td>1 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>• Squamous cell carcinoma</td>
<td></td>
<td>3 (13.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Others</td>
<td>12 (54.5%)</td>
<td>9 (60.0%)</td>
<td>1 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>Lymph node status:</td>
<td>15 (68.18%)</td>
<td>--</td>
<td>--</td>
<td>0.03*</td>
</tr>
<tr>
<td>• N0-N1</td>
<td>7 (31.82%)</td>
<td>15 (100%)</td>
<td>3 (100%)</td>
<td></td>
</tr>
<tr>
<td>• N2-N3</td>
<td>15 (68.18%)</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
</tbody>
</table>
| ECOG: Eastern Cooperative Oncology Group
PR: partial response, SD: stable disease, PD: progressive disease
* : significant P value
Survival results with the Use of Chemoradiotherapy

**DISCUSSION**

Despite intensive investigation, the prognosis for patients with lung cancer, up to 87% of whom have non-small cell lung cancer (NSCLC) at diagnosis, remains poor, with an estimate 5-year survival rate of only 15%.

The standard treatment of locally advanced unresectable NSCLC is combined chemotherapy and thoracic radiation, based on the results of several randomized phase III trials subsequent trials have demonstrated the superiority of concurrent chemoradiotherapy and radiotherapy over sequential approach at the expense of increased toxicity, in particular severe esophagitis.

Concurrent chemoradiotherapy improves overall survival (OS) of patients with locally advanced NSCLC compared with sequential chemoradiotherapy. Platinum-based polychemotherapy is considered the standard treatment. The most active combination in this situation is cisplatin-etoposide which provides a median survival of 23 months (overall survival at 3 years of 26.1%, progression-free survival around 10 months).

In the present study, the partial response rate was not significantly higher in patients treated with concurrent versus sequential chemoradiotherapy (55% vs. 40%), but a significant response rate was noted to concomitant chemoradiotherapy than sequential in stage III A and B. This is in agreement with the results of the study done by Fournel et al. who reported a better response rate of (54% vs. 49%) in the concurrent versus sequential chemoradiotherapy. Similar to the current study findings, stage IIIA patients gained particular benefit from concomitant chemoradiotherapy by achieving an overall response rate almost 20% higher than those treated with radiotherapy alone.

These data indicate that concurrent chemoradiotherapy is helpful in improving response and survival than sequential one; this is also seen in previous studies done by Zatloukal et al. and Wang et al.
The presence of N2-N3 disease was found to be an adverse prognostic factor in the present study (Table 4,5) but in the study done by Saynak et al., non-epidermoid histology and Karnofsky Performance Status less than 70 were found as additional prognostic factors.

Median survival times in the current study were 20 months versus 12 months ($P<0.001$) for patients treated with concurrent versus sequential chemoradiotherapy which is similar to the results of the study done by Crvenkova et al., who reported a median survival 13 months for patients treated with sequential chemoradiotherapy and 22 months for patients treated with concurrent chemoradiotherapy ($P<0.001$). Conversely, in a study done by Saynak et al., a similar median survival was reported in both groups (14.5 vs. 14.6 months) for patients treated with sequential and concomitant chemoradiotherapy respectively, mostly due to the inclusion of patients with stage III B only in his study.

The 1- and 2-year survival rates were 68% and 42% in the concurrent group and 48% and 24% in the sequential group. This was noted in the current study which is in agreement with the statistical significant difference in 1- and 2-year survival rates of 73.6% and 39.7% in the concurrent group and 45.4% and 13.7% in the sequential group in a study done by Crvenkova et al. Another study done by Fournel et al. also reported a better 2-year survival rates in the concurrent arm than sequential arm(39% vs 26%, respectively).

In the present study, Progression-free survival (PFS) was significantly higher in patients treated with concurrent than sequential chemoradiotherapy (15 vs. 9 months $P<0.001$). This is in agreement with the significant difference in DFS in the study done by Crvenkova et al. Another study done by Fournel et al. also reported a better 2-year survival rates in the concurrent arm than sequential arm.

The 1-year progression-free survival rate was 60% which is lower than the 1-year PFS results reported by Wang et al.(75%), the difference in local control rates may be due to the use of three dimensional conformal radiotherapy in his study.

Both treatments were well tolerated; no grade 4 toxicity was reported in both groups. Notably, little toxicity reported with an increased incidence significantly, especially acute esophagitis and leukopenia, in patients treated with concomitant than sequential chemoradiotherapy. These results were in agreement with results reported by Crvenkova et al. but grade 3 esophagitis in his study was a reason for radiotherapy interruption during conformal three-dimensional radiotherapy may be due to the use of high dose chemotherapy concomitantly with radiotherapy.

In an attempt to improve loco-regional control in stage III A-B NSCLC, a three armed randomized trial comparing accelerated radiotherapy or concurrent daily or weekly chemotherapy with conventional radiotherapy was tested by Nyman et al.,

Treatment results are quite equal by intensifying the loco-regional treatment either by accelerated fractionated radiotherapy or daily or weekly concurrent chemoradiotherapy both in term of survival, toxicity and quality of life.

A phase III randomized study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable NSCLC done by Berghmans et al. They concluded that consolidation chemoradiotherapy seems less toxic with a better observed response rates and survival.

It remains to be determined whether induction chemotherapy before concurrent chemoradiotherapy or concurrent chemoradiotherapy followed by consolidation chemotherapy is the most effective sequence, but the latter approach has produced a longer survival times. It is important to note that some patients with locally advanced NSCLC do not meet the tumor volume requirements when planning radiotherapy at baseline. Induction chemotherapy might potentially rescue some patients presenting with bulky disease if a policy of encompassing postchemotherapy tumor volume is adopted.

CONCLUSION

In conclusion, the addition of chemotherapy to radiation concomitantly prolongs survival than sequential therapy in locally advanced non-small cell lung cancer patients with acceptable adverse event profiles.

REFERENCES


